Management of hepatitis C infection before and after liver transplantation

World Journal of Gastroenterology

Volumn 21, Issue 15, 2015, Pages 4447-4456

  Fagiuoli, Stefano ^a   Ravasio, Roberto ^b   Lucà, Maria Grazia ^a   Baldan, Anna ^a   Pecere, Silvia ^a   Vitale, Alessandro ^c   Pasulo, Luisa ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b PHarmES Sas Studi di Valutazione Economica   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chronic hepatitis C; Decompensated cirrhosis; Hepatitis C virus; Interferon free treatment; Orthotopic liver transplantation

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; CORTICOSTEROID; CYCLOSPORIN; DACLATASVIR; DASABUVIR; INTERFERON; MYCOPHENOLATE MOFETIL; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; IMMUNOSUPPRESSIVE AGENT;

ACUTE HEPATITIS C; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL STUDY; CORRELATION ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ECONOMIC ASPECT; GENOTYPE; GRAFT SURVIVAL; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MORTALITY; PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; SURVIVAL; SUSTAINED VIRAL RESPONSE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COST; DRUG EFFECTS; ECONOMICS; END STAGE LIVER DISEASE; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PATIENT SELECTION; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PATIENT SELECTION; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84928193501     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i15.4447     Document Type: Article

References (70)

1. European Association for Study of Liver . EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]
2. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, Harper AM, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 2013; 13 Suppl 1: 73-102 [PMID: 23237697 DOI: 10.1111/ajt.12021]
3. Italian Association for the Study of the Liver, (Italian Society of Infectious, Tropical Diseases), Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42: 81-91 [PMID: 19748329 DOI: 10.1016/j.dld.2009.08.001]
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28-S34 [PMID: 14586892 DOI: 10.1053/jlts.2003.50248]
5. Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, Rufian S, de la Mata M, Briceño J, Cillero PL, Heaton N. Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol 2013; 5: 237-250 [PMID: 23717735 DOI: 10.4254/wjh.v5.i5.237]
6. Davis GL. New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation. Liver Transpl 2003; 9: S114-S119 [PMID: 14586906 DOI: 10.1053/jlts.2003.50246]
7. Agarwal K, Barnabas A. Treatment of chronic hepatitis C virus infection after liver transplantation. Dig Liver Dis 2013; 45 Suppl 5: S349-S354 [PMID: 24091115 DOI: 10.1016/j.dld.2013.07.014]
8. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, Machicao VI, Chaoru C, Nelson DR. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-1071 [PMID: 19718647 DOI: 10.1002/lt.21784]
9. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396 [PMID: 12927925]
10. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012; 32 Suppl 1: 120-128 [PMID: 22212582 DOI: 10.1111/j.1478-3231.2011.02714.x]
11. Colombo M, Fernández I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Moreno C, Streinu-Cercel A, Verheyen A, Iraqi W, DeMasi R, Hill A, Läuffer JM, Lonjon-Domanec I, Wedemeyer H. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 2014; 63: 1150-1158 [PMID: 24201995 DOI: 10.1136/gutjnl-2013-305667]
12. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441 [PMID: 23669289 DOI: 10.1016/j.jhep.2013.04.035]
13. Joshi D, Carey I, Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther 2013; 37: 659-671 [PMID: 23432320 DOI: 10.1111/apt.12260]
14. Londoño MC, Crespo G, Forns X. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant 2013; 18: 271-278 [PMID: 23665543 DOI: 10.1097/MOT.0b013e3283614aca]
15. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnú L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587 [PMID: 17326216 DOI: 10.1002/hep.21492]
16. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-828, 288.e1 [PMID: 19948249 DOI: 10.1016/j.cgh.2009.11.018]
17. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
18. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-1660 [PMID: 22610658 DOI: 10.1002/hep.25842]
19. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684 [PMID: 17133499 DOI: 10.1002/hep.21440]
20. Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460 [PMID: 16890599 DOI: 10.1053/j.gastro.2006.05.016]
21. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023; discussion 947 [PMID: 15057741]
22. Berenguer M, Charco R, Manuel Pascasio J, Ignacio Herrero J. Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver Int 2012; 32: 712-731 [PMID: 22221843 DOI: 10.1111/j.1478-3231.2011.02731.x]
23. Guido M, Fagiuoli S, Tessari G, Burra P, Leandro G, Boccagni P, Cillo U, Naccarato R, Rugge M. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697-700 [PMID: 11950819]
24. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol 2013; 13: 16 [PMID: 23324473 DOI: 10.1186/1471-230X-13-16]
25. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262 [PMID: 16025497 DOI: 10.1002/hep.20793]
26. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-1762 [PMID: 22821361 DOI: 10.1002/hep.25976]
27. Braithwaite A, Aguilera V, Vinaixa C, Garcia M, Benlloch S, Rubin A, Prieto M, Berenguer M. Triple therapy for HCV cirrhosis in liver transplant candidates. High rate of prevention of HCV recurrence after liver transplantation (LT) in well selected patients [P1207]. J Hepatol 2014; 60 (Suppl): S361-S522
28. Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-59 [PMID: 15876467 DOI: 10.1016/j.jhep.2005.02.015]
29. Gurakar A, Fagiuoli S, Hassanein T, Kingery L, Wright HI, Ersoz S, Caraceni P, Gavaler JS, Van Thiel DH. Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection? Eur J Gastroenterol Hepatol 1994; 6: 429-432
30. Ponziani FR, Gasbarrini A, Pompili M, Burra P, Fagiuoli S. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc 2011; 43: 291-295 [PMID: 21335208 DOI: 10.1016/j.transproceed.2010.09.102]
31. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881 [PMID: 19938138 DOI: 10.1002/lt.21954]
32. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 Suppl 2: S36-S44 [PMID: 18825724 DOI: 10.1002/lt.21646]
33. Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011; 3: 198-204 [PMID: 21866251 DOI: 10.4254/wjh.v3.i7.198]
34. Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. Transplant Proc 2011; 43: 3824-3828 [PMID: 22172854 DOI: 10.1016/j.transproceed.2011.08.103]
35. Ikegami T, Shirabe K, Yoshizumi T, Furusyo N, Kotoh K, Kato M, Shimoda S, Soejima Y, Motomura T, Fukuhara T, Maehara Y. Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation. Transplantation 2013; 95: e38-e42 [PMID: 23507656 DOI: 10.1097/TP.0b013e318283a82e]
36. Takeishi K, Shirabe K, Toshima T, Ikegami T, Morita K, Fukuhara T, Motomura T, Mano Y, Uchiyama H, Soejima Y, Taketomi A, Maehara Y. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. Surg Today 2011; 41: 1016-1019 [PMID: 21748625 DOI: 10.1007/s00595-010-4392-z]
37. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86 [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018]
38. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-1470 [PMID: 22941516 DOI: 10.1002/lt.23542]
39. Burton J, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety, and tolerability [abstract #LB01]. American Transplant Congress: ATC, 2012
40. de Oliveira Pereira AP, Shin HJ, Safdar A, Tobias H, Gelb B, Morgan G, Diflo T, Winnick A, Teperman L. Post liver transplant therapy with telaprevir for recurrent hepatitis C [abstract #1369]. American Transplant Congress: ATC, 2012
41. Forns X, Samuel D, Mutimer D, Fagiouli S, Navasa M, Agarwal K, Berenguer M, Colombo M, Herzer K, Nevens F, Van Solingen-Ristea R, Luo D, Dierynck I, Witek J. Interim SVR12 results from the telaprevir phase 3b replace study in treatment-naïve stable liver transplant patients with genotype 1 HCV infection [P1185]. J Hepatol 2014; 60 (Suppl): S361-S522
42. Pungpapong S, Murphy J, Henry T, Satyanarayana R, Rosser B, Yataco M, Harnois D, Patel T, Keaveny A. Initial experience utilizing telaprevir with peginterferon and ribavirin for treatment of hepatitis C genotype 1 after liver transplantation [abstract #1367]. American Transplant Congress: ATC, 2012
43. Werner CR, Egetemeyr DP, Nadalin S, Königsrainer A, Malek NP, Lauer UM, Berg CP. Telaprevir-triple therapy of recurrent HCV genotype 1 (G1) infection after liver transplantation (LTx): SVR 24 results [P902]. J Hepatol 2014; 60 (Suppl): S361-S522
44. Rogers CC, Stevens DR, Kim M, Ghaziani T, Malik R, Curry MP. Telaprevir can be used safely with concomitant tacrolimus in the post-transplant setting [abstract #1372]. American Transplant Congress: ATC, 2012
45. Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso A-M, Vittecoq D, Samuel D, Taburet A-M, Duclos-Vallee J-C. Anti-hepatitis C (HCV) triple therapy with protease inhibitors in HIV/HCV co-infected patients after liver transplantation [P1237]. J Hepatol 2014; 60 (Suppl): S361-S522
46. Reddy KR, Everson GT. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. Hepatology 2013; 58: 1181-1184 [PMID: 23908010 DOI: 10.1002/hep.26612]
47. Sam T, Tichy E, Emre S, Schilsky M. Pharmacokinetic effects of boceprevir co-administration on cyclosporine exposure in liver transplant recipients [abstract #1370]. American Transplant Congress: ATC, 2012
48. Schilsky M, Sam T, Tichy E, Caldwell C, Jakab S, Emre S. Boceprevir, peginterferon and ribavirin (PEGIFN/RIB) as triple antiviral therapy for severe recurrent hepatitis C post liver transplant: an early single center experience [abstract #1377]. American Transplant Congress: ATC, 2012
49. Alves de Mattos A, Zambam de Mattos A. Treatment of HCV infection in patients with cirrhosis. Ann Hepatol 2010; 9 Suppl: 80-83 [PMID: 20714001]
50. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650 [PMID: 12612903 DOI: 10.1053/gast.2003.50095]
51. Fredrick RT, Hassanein TI. Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. J Clin Gastroenterol 2005; 39: S14-S22 [PMID: 15597023]
52. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 Suppl 1: S88-100 [PMID: 22300469 DOI: 10.1016/S0168-8278(12)60010-5]
53. Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver 2014; 8: 471-479 [PMID: 25228970 DOI: 10.5009/gnl14083]
54. Forns X, Prieto M, Charlton M, McHutchison JG, Symonds WT, Denning J, Brandt-Sarif T, Chang P, Kivett V, Fontana RJ, Baumert TF, Coilly A, Castells L, Habersetzer F. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation [abstract 062]. J Hepatol 2014; 60 (Suppl): S23-S44
55. Gilead Sciences I. FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection, 2013
56. Curry MP, Forns X, Chung RT, Terrault NA, Brown RS, Jr., Fenkel JM, Gordon F, O'Leary JG, Kuo A, Schiano T, Everson GT, Schiff ER, Befeler A, McHutchison JG, Symonds WT, Denning J, McNair L, Arterburn S, Moonka D, Gane E, Afdhal N. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation [AASLD abstract 213]. Hepatology 2013; 58: 314A
57. Samuel D, Charlton M, Gane E, Brown J, R., Curry M, Kwo P, Fontana R, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Denning J, McNair L, Arterburn S, Terrault N, Forns X, Manns M. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective multicenter study [P1232]. J Hepatol 2014; 60 (Suppl): S361-S522
58. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605 [PMID: 23593993 DOI: 10.1111/ajt.12209]
59. Pellicelli AM, Lionetti R, Montalbano M, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M. Sofosbuvir and daclatasvir for recurrent hepatitis C after liver transplantation: potent antiviral activity but lack of clinical benefit if treatment is given too late [P1312]. J Hepatol 2014; 60 (Suppl): S523-S537
60. Bárcena R, Moreno A, Rodríguez-Gandía MA, Albillos A, Arocena C, Blesa C, García-Hoz F, Graus J, Nuño J, López-Hervás P, Gajate L, Martínez A, Bermejo T, Mateos ML, Del Campo S. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013; 58: 421-426 [PMID: 23073223 DOI: 10.1016/j.jhep.2012.10.009]
61. Mariño Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, Navasa M, Forns X. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 2013; 58: 415-420 [PMID: 23063567 DOI: 10.1016/j.jhep.2012.09.034]
62. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52: 951-952 [PMID: 20413176 DOI: 10.1016/j.jhep.2010.02.002]
63. Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown Jr. R, Gordon F, Levitsky J, Terrault N, Burton Jr. J, Xie W, Setze C, Badri P, Vilchez RA, Forns X. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/R/ABT-267 ABT-333 ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection [P0114]. J Hepatol 2014; 60 (Suppl): S45-S66
64. Lang M, Polywka S, Kluwe J, Fischer L, Jordan S, Lütgehetmann M, Nashan B, Lohse AW, Sterneck M. First case report of a patient with fibrosing cholestatic hepatitis C after liver transplantation treated with sofosbuvir and simeprevir [P875]. J Hepatol 2014; 60 (Suppl): S361-S522
65. Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int 2013; 26: 527-534 [PMID: 23517333 DOI: 10.1111/tri.12085]
66. Libro Bianco AISF. Proposta per un piano nazionale per il controllo delle malattie epatiche. Definizione ambiti e possibili interventi: Fondazione Italiana per la Ricerca in Epatologia, 2011
67. Carosi G, Caporaso N, Gardini I, Mazzotta F, Prati D, Rizzetto M, Rossi A, Salvagnini M, Taliani G. Epatiti Summit. Un'emergenza sommersa: opinioni e strategie a confronto, 2010
68. Ciampichini R, Scalone L, Fagiuoli S, Fusco F, Gaeta L, Del prete A, Gardini I, Mantovani L. Societal burden in hepatitis C patients: the COME study results. Value Health 2012; 15: A138
69. Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Svegliati Baroni G, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Cillo U, Fagiuoli S, on behalf of the Liver Transplantation NITp working group. Potential net health benefit of pre-transplant Sofosbuvir to prevent recurrence of HCV infection after liver transplantation: A multicenter, cohort model study. Dig Liver Dis 2014; 46 Suppl 4: e.132-e.133 [DOI: 10.1016/j.dld.2014.08.012]
70. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. PLoS One 2013; 8: e80528 [PMID: 24265827 DOI: 10.1371/journal.pone.0080528]